Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.

Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.

Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.

Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.

The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for clinicians using PREVENT-ASCVD Equations for Risk-Based Lipid Management.

Here are the top things for women’s health clinicians to know.

Here are the top things for women’s health clinicians to know.

The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for women’s health clinicians to know.

Here are the top things for geriatric clinicians to know.

Here are the top things for geriatric clinicians to know.

The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for geriatric clinicians to know.

Here are the top things for pediatric clinicians to know.

Here are the top things for pediatric clinicians to know.

The 2026 Guideline on the Management of Dyslipidemia was recently published. Here are the top things for pediatric clinicians to know.

Here are the top 10 things for health care professionals to know.

Here are the top 10 things for health care professionals to know.

The 2026 Guideline on the Management of Dyslipidemia was recently published.

Here are the top 10 things for health care professionals to know.

That’s a wrap on #EpiLifestyle26! Thanks to everyone who helped take this meeting to a whole new level.

That’s a wrap on #EpiLifestyle26! Thanks to everyone who helped take this meeting to a whole new level.

Let’s meet again at #EpiLifestyle27


📅 March 2-5, 2027
📍 Boston, Massachusetts

Words of the week at #EpiLifestyle26.

Words of the week at #EpiLifestyle26. What do you have to add?

Meet the authors of the 2026 ACC/AHA Dyslipidemia Guideline!

Meet the authors of the 2026 ACC/AHA Dyslipidemia Guideline!

Join us at 8 a.m. Thursday for an in-depth discussion of the updated recommendations in the new guideline – an update to the 2018 joint cholesterol guideline – and their implications for clinical practice.

#EPILifestyle26

Welcome to Boston and #EPILifestyle26!

Welcome to Boston and #EPILifestyle26! Hit repost and share the big moments you’re looking forward to most.

Let’s make this week unforgettable, together.

Where potential meets mission.

Fuel your discoveries with funding, mentorship and the powerful research network of the American Heart Association. We’re here to help you thrive.

Your research. Our support. A healthier future.

From bold ideas to lifesaving breakthroughs, your research starts here. Grant applications are open to help you shape the future of health.

Advancing science. Advancing you.

Fuel your discoveries with funding, mentorship and the powerful research network of the American Heart Association. Don’t miss a chance to advance science and save lives. Applications are open.

ISC26 is 50 days away

It’s not too late to save your spot for #ISC26! Be part of this global gathering of experts changing the future of stroke and brain health science.

See you in New Orleans in 50 days!

Turn Your Passion Into Progress.

Your research has the power to save lives. An American Heart Research Awards gives you the support to make it happen. Applications are open!

Scientific Sessions 2025 Late Breaking Science 1 of 3

Scientific Sessions 2025 Late Breaking Science 2 of 3

Scientific Sessions 2025 Late Breaking Science 3 of 3

ICYMI here are results from all 17 LBS presentations at #AHA25. Missed them?

Check them out on Scientific Sessions OnDemand coming in early December.

Research Awards: fueling breakthroughs. Empowering you.

Advance your research with the support you deserve. We anticipate that about 1,000 grants will be awarded this year to help you advance science and save lives. Applications are open now.

DAPT-MVD results presented at #AHA25

DAPT-MVD results presented at #AHA25

CELEBRATE results presented at #AHA25

CELEBRATE results presented at #AHA25

The TOP trial is a parallel, single-blind, randomized, clinical superiority trial, N=1424 that sought to determine whether liberal versus restrictive transfusion strategy after major general and vascular surgery reduces adverse outcomes in high cardiac risk patients.

Sunil Rao, MD on the results.

ANGPTL3, presented at #AHA25 showed gene editing demonstrates few adverse events.

More from Dr. Harrington👇👇

Calling all coffee drinkers! Dr. Khan has good news from the DECAF trial presented at #AHA25. ☕☕☕

DECAF results presented at #AHA25

DECAF results presented at #AHA25

What is the potential clinical impact of the OPTIMA trial?

Here is one prediction. #AHA25

In patients with AF who are stable beyond one year of drug-eluding stent implantation NOAC monotherapy provides a simple and safe long-term therapy versus combination therapy.

📢 Adding evolocumab to lipid-lowering therapy significantly reduced the risk of a first major CV event in patients without prior heart attack or stroke.

#AHA25 ⬇️

The study demonstrates that DR10624 can lead to significant reductions in triglycerides with favorable safety and tolerability results.

Shayan Mohammadmoradi's, MS, PhD take on the data presented at #AHA25

PREVENT equation 🤝 cardiovascular kidney metabolic health

Learn more about CKM and PREVENT at #AHA25

VESALIUS-CV results presented at #AHA25

VESALIUS-CV results presented at #AHA25

ANGPTL3 results presented at #AHA25

ANGPTL3 results presented at #AHA25

DR10624 results presented at #AHA25

DR10624 results presented at #AHA25